Resumen: Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva
Saturday, September 26, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Mirum Pharmaceuticals and Incyte have announced that the FDA has approved Atebrioz™ (zilurgisertib) for the treatment of heterotopic ossification in patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP). This approval marks a significant advancement in treatment options for this rare condition, providing new hope for patients and their families.
Market Sentiment Analysis
POSITIVE FACTORS
FDA approval for Atebrioz™ (zilurgisertib) is a significant milestone.
The drug is now available for both adult and pediatric patients.
It targets a rare condition, offering hope to affected individuals.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
2.8%
average across 14 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
Blinded CDCA
Phase 3 · CTX
Full Press Release Details
FOSTER CITY (California) y WILMINGTON (Delaware)--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) e Incyte (Nasdaq:INCY) anunciaron hoy que la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos aprobó las tabletas de Atebrioz™ (zilurgisertib) para reducir el volumen de nueva osificación heterotópica (HO) total en pacientes adultos y pediátricos desde 12 años con fibrodisplasia osificante progresiva (FOP). El comunicado en el idioma original es la versión oficial y
Frequently Asked Questions
What is Atebrioz™ used for?
Atebrioz™ (zilurgisertib) is approved to reduce heterotopic ossification in FOP patients.
Who can use Atebrioz™?
The drug is approved for both adult and pediatric patients aged 12 and older.
Which companies developed Atebrioz™?
Atebrioz™ was developed by Mirum Pharmaceuticals and Incyte.
What condition does Atebrioz™ target?
It targets fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder.